Scarica l'app Stockscreener
1.66
0.00%
0.00
Dopo l'orario di chiusura:
1.66
Akebia Therapeutics Inc Borsa (AKBA) Ultime notizie
Analysts Are Optimistic We'll See A Profit From Akebia Therapeutics, Inc. (NASDAQ:AKBA) - Yahoo Finance
Akebia Therapeutics, Inc. (NASDAQ:AKBA) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Why Akebia Therapeutics Inc AX9 stock attracts HNW investorsPortfolio Return Report & Reliable Entry Point Alerts - moha.gov.vn
Q32 Bio Shares Soar After Offloading Phase 2 Complement Drug to Akebia - MSN
Will Akebia Therapeutics Inc. (AX9) stock sustain dividend payoutsNew Guidance & Free Technical Pattern Based Buy Signals - Newser
Analysts Offer Insights on Healthcare Companies: NRX Pharmaceuticals (NRXP), Akebia Therapeutics (AKBA) and Ionis Pharmaceuticals (IONS) - The Globe and Mail
Q32 Bio sells complement inhibitor ADX-097 to Akebia for $12M upfront - MSN
Is Akebia Therapeutics Inc. (AX9) stock testing key support2025 Key Highlights & Free Real-Time Volume Trigger Notifications - Newser
Bronstein, Gewirtz & Grossman, LLC Encourages Akebia Therapeutics, Inc. (AKBA) Shareholders to Inquire about Securities Investigation - ACCESS Newswire
Pfizer-backed biotech lands $120M, plus other Boston-area life science news - The Business Journals
With Akebia Therapeutics Stock Sliding, Have You Assessed The Risk? - Trefis
Deal Watch: Akebia Gets Phase II Alopecia Areata Candidate From Cost-Conscious Q32 - Citeline News & Insights
Akebia Therapeutics (NASDAQ:AKBA) Receives Buy Rating from BTIG Research - MarketBeat
Akebia Therapeutics (NASDAQ:AKBA) Receives "Buy" Rating from HC Wainwright - MarketBeat
Why Akebia Therapeutics Inc. (AX9) stock could be top winnerQuarterly Profit Report & Free Weekly Watchlist of Top Performers - Newser
Akebia Therapeutics announces establishment of rare kidney disease pipeline - MSN
HC Wainwright & Co. Reiterates Akebia Therapeutics (AKBA) Buy Recommendation - MSN
BTIG Reiterates Buy Rating for Akebia Therapeutics (AKBA) | AKBA Stock News - GuruFocus
This Penny Biotech Stock Just Doubled on a Key Acquisition. Should You Buy Shares Here? - Yahoo Finance
Akebia Therapeutics stock rating reiterated at Buy by H.C. Wainwright - Investing.com Canada
HC Wainwright & Co. Reiterates Buy Rating for AKBA, Price Target Unchanged | AKBA Stock News - GuruFocus
QTTB Stock Explodes Nearly 95%: Akebia Deal Transforms Q32 Bio’s Future - Bitget
Is Akebia Therapeutics Inc a good long term investmentStock Market Trends & Access Free Tools and Start Investing - earlytimes.in
Can Akebia Therapeutics Inc. (AX9) stock sustain revenue momentumEarnings Overview Summary & Low Risk High Reward Ideas - Newser
Is Akebia Therapeutics Inc. (AX9) stock protected from inflationTrade Volume Report & Free Technical Confirmation Trade Alerts - Newser
Cyclerion Receives Milestone Payment from Akebia - TipRanks
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Akebia Therapeutics (Nasdaq: AKBA) announces 22,576-share inducement grant - Stock Titan
Q32 Bio (QTTB) Stock Explodes After $592 Million Akebia Deal – Latest News, Analyst Targets and 2027 Outlook - ts2.tech
Q32 sells rare kidney disease drug to Akebia for $12M up front - BioWorld MedTech
Q32 Bio skyrockets as it sells complement inhibitor ADX-097 - The Pharma Letter
Akebia Therapeutics, Inc. Announces Establishment of Rare Kidney Disease Pipeline - marketscreener.com
Why Is Small-Cap Q32 Bio Stock Soaring On Monday? - Benzinga
Akebia Therapeutics Sets Rare Kidney Drug Plan After Q32 Bio Deal - marketscreener.com
Q32 Bio stock rockets after selling Phase 2 complement inhibitor to Akebia - Investing.com Nigeria
Akebia announces establishment of rare kidney disease pipeline - marketscreener.com
Q32 Bio Sells Complement Inhibitor ADX-097 - citybiz
Akebia Therapeutics (AKBA) Expands Pipeline with Rare Kidney Dis - GuruFocus
Akebia Therapeutics (AKBA) Acquires Phase 2 Drug from Q32 Bio - GuruFocus
Akebia Therapeutics (AKBA) Acquires Phase 2 Inhibitor ADX-097 - GuruFocus
Q32 Bio sells complement inhibitor ADX-097 to Akebia - TipRanks
Akebia Therapeutics Acquires Global Rights to ADX-097 - TipRanks
Q32 Bio Sells ADX-097 to Akebia Therapeutics - TipRanks
Akebia Announces Establishment of Rare Kidney Disease Pipeline - The Manila Times
Akebia Therapeutics Establishes Rare Kidney Disease Pipeline with Acquisition of AKB-097 and Initiation of Praliciguat Phase 2 Trial - Quiver Quantitative
Geode Capital Management LLC Acquires 1,043,718 Shares of Akebia Therapeutics, Inc. $AKBA - MarketBeat
Akebia Therapeutics, Inc. Initiates Phase 2 Clinical Trials for the Treatment of Focused Segmental Glomerulosclerosis Using Praliciguat - marketscreener.com
Is Akebia Therapeutics Inc. stock a buy on dips2025 Volume Leaders & Free Safe Capital Growth Stock Tips - BỘ NỘI VỤ
Akebia Therapeutics (NASDAQ:AKBA) Downgraded by Wall Street Zen to "Buy" - MarketBeat
Why analysts recommend Akebia Therapeutics Inc. (AX9) stockQuarterly Portfolio Review & Weekly Momentum Stock Picks - BỘ NỘI VỤ
Why Akebia Therapeutics Inc. stock is a must watch in 2025Quarterly Growth Report & Real-Time Volume Spike Alerts - moha.gov.vn
Is Akebia Therapeutics Inc. (AX9) stock a top pick for value investors2025 Risk Factors & Weekly High Momentum Picks - BỘ NỘI VỤ
Akebia Therapeutics Hits New 52-Week Low at $1.49 - Markets Mojo
Akebia Therapeutics (NASDAQ:AKBA) Has A Pretty Healthy Balance Sheet - 富途牛牛
Akebia Therapeutics to Present at the Piper Sandler 37th Annual Healthcare Conference - The Manila Times
Implied Volatility Surging for Akebia Therapeutics Stock Options - MSN
Bronstein, Gewirtz & Grossman, LLC Is Investigating Akebia Therapeutics, Inc. (AKBA) And Encourages Investors to Connect - ACCESS Newswire
Akebia Therapeutics Inc. (AKBA) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
1.48%
0.09%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):